Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Assessment of soluble cell adhesion molecules and soluble CD40 ligand levels in ankylosing spondylitis.

Sari I, Alacacioglu A, Kebapcilar L, Taylan A, Bilgir O, Yildiz Y, Yuksel A, Kozaci DL.

Joint Bone Spine. 2010 Jan;77(1):85-7. doi: 10.1016/j.jbspin.2009.07.005. Epub 2009 Dec 22. No abstract available.

PMID:
20022783
2.

A new strategy of drug treatment in NSAID--unresponsive ankylosing spondylitis.

Chogle AR, Mishra H, Chakravarty A.

J Assoc Physicians India. 2007 May;55:380; author reply 380-1. No abstract available.

PMID:
17844703
3.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

4.

Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.

Genre F, Miranda-Filloy JA, López-Mejias R, Carnero-López B, Ochoa R, Rueda J, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.

Ann Rheum Dis. 2013 Jul;72(7):1265-7. doi: 10.1136/annrheumdis-2012-203169. Epub 2013 Mar 12. No abstract available.

PMID:
23482472
5.

Intraarticular injection of infliximab.

Sakellariou GT, Kakavouli G, Chatzigiannis I.

J Rheumatol. 2006 Sep;33(9):1912-3; author reply 1913. No abstract available.

PMID:
16960955
6.

Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?

Goodemote P, Jamieson B, Hoffman R.

J Fam Pract. 2007 Nov;56(11):933-4, 937. No abstract available.

PMID:
17976342
7.

Novel therapies for ankylosing spondylitis.

Maksymowych WP.

Curr Rheumatol Rep. 2005 Jun;7(3):182-7. Review.

PMID:
15918993
8.

Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.

Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Gómez-Acebo I, Blanco R, Ochoa R, Rueda-Gotor J, Pina T, González-Juanatey C, Llorca J, González-Gay MA.

Ann Rheum Dis. 2014 May;73(5):941-3. doi: 10.1136/annrheumdis-2013-204484. Epub 2013 Dec 9. No abstract available.

PMID:
24323393
9.

Established criteria for disease controlling drugs in ankylosing spondylitis.

Gladman DD.

Ann Rheum Dis. 2003 Sep;62(9):793-4. No abstract available.

10.

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group..

Ann Rheum Dis. 2003 Sep;62(9):817-24. Review.

11.

New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Sieper J, Braun J.

Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii58-61. Review.

12.
13.

BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.

Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P; BSR Standards, Guidelines and Audit Working group..

Rheumatology (Oxford). 2005 Jul;44(7):939-47. Epub 2005 May 18. No abstract available.

PMID:
15901904
14.

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

Semin Arthritis Rheum. 2004 Feb;33(4):283-8.

PMID:
14978666
15.

The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis.

Borman P, Ayhan F, Ceceli E.

Rheumatol Int. 2010 Nov;30(12):1689-90. doi: 10.1007/s00296-009-1283-y. Epub 2009 Dec 15. No abstract available.

PMID:
20012962
16.

Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.

Schatteman L, Gyselbrecht L, De Clercq L, Mielants H.

J Rheumatol. 2006 Jan;33(1):82-5. Epub 2005 Nov 15.

PMID:
16292792
17.

Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?

Van den Bosch F, De Keyser F, Mielants H, Veys EM.

Arthritis Res Ther. 2005;7(3):121-3. Epub 2005 Apr 11. Review.

19.

The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.

Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.

Rheumatology (Oxford). 2005 Oct;44(10):1277-81. Epub 2005 Aug 16.

PMID:
16105913
20.

Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.

Kassimos DG, Garyfallos A, Delamere J, Whallett A, Kitas GD.

Rheumatology (Oxford). 2003 Mar;42(3):490. No abstract available.

PMID:
12626807

Supplemental Content

Support Center